Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 3, 2026, 7:15 AM ET
Decoy Therapeutics reported a third quarter 2026 business update, expecting to file a CTA or IND for its pan-coronavirus candidate in 2H 2027 and holding $8.1 million in cash at September 30, 2026.
$DCOYBiotechnologyClinical evidenceDevelopment risk
DCOY Stock Hub: Decoy Therapeutics News, Antivirals and Clinical Entry
On September 29, 2026 Decoy reported that a single intranasal dose of DCOY-CoV kept drug levels above its designed antiviral concentrations for up to seven days in nasal mucosal and lung tissue in preclinical studies, a profile that supports a once-weekly dosing hypothesis. On November 3 the company said it expects to file a Clinical Trial Application (CTA) or Investigational New Drug (IND) application in the second half of 2027 to start a Phase 1 trial of its pan-coronavirus candidate, and reported cash of $8.1 million at September 30, 2026, including about $2.5 million of restricted Gates Foundation grant funding. Funding is the other half of the story: about $3.85 million raised on September 23 through a warrant inducement, new warrants at $3.25, and a June 30 going-concern warning.
Full research report · PDF
Decoy Therapeutics ($DCOY), research as of October 20, 2026
16 pages covering The archived report examines peptide-based antiviral design, tissue-exposure findings and the difference between cell or animal observations and human efficacy. It follows the proposed Animal Rule route, respiratory development, restricted grant cash, September warrant inducement, the resale registration and financing needs before planned clinical entry. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next company clinical target
Second half of 2027
CTA or IND filing to start the Phase 1 trial of the pan-coronavirus candidate, followed by a Phase 2a human challenge trial at hVivo; company expectation from the November 3 business update. Primary source
The November 3 release reports cash and share count at September 30 but includes no financial statements and no conference call.
DCOY stock at a glance
Close · November 2, 2026
$1.035
Regular-session close; -3.27% versus $1.07 on October 30, 2026.
Cash including restricted funds · September 30, 2026
$8.1M
Company release of November 3, 2026; includes about $2.5M of restricted Gates Foundation grant funding. The October 16 prospectus had shown ~$8.0M.
Restricted grant cash · June 30, 2026
~$2.7M
Q2 Form 10-Q; Gates Foundation restrictions.
Operating cash used · first half 2026
$5.54M
Q2 Form 10-Q; six-month cash flow, not quarterly burn.
Common shares
2,385,282
September 30, 2026, per the November 3 release (the October 6 prospectus showed the same count); not fully diluted.
Warrants outstanding · June 30, 2026
4,699,381
Q2 Form 10-Q; before the September 22–23 warrant transactions; different instruments.
Series B exercise · closed September 23, 2026
~$3.85M gross
Form 8-K; 1,184,434 warrants at $3.25, before fees and expenses.
Shares under $3.25 warrants · September 23, 2026
~4.15M
New, Series A and Series C warrants; Merlintrader sum of 8-K and 10-Q terms; not issued shares.
Where Decoy Therapeutics stands now
November 3, 2026 update. In its third-quarter 2026 business update Decoy said it expects to file a CTA or IND application in the second half of 2027 to begin a Phase 1 trial of its pan-coronavirus candidate, followed by a Phase 2a human challenge trial at hVivo, a UK-based contract research organization; these are company expectations. In preclinical studies an optimized lead candidate showed potential for once-weekly dosing, compared with daily dosing for earlier candidates. The company is also exploring a pan-filovirus program targeting Ebola, Marburg and related viruses, says it has met with U.S. government and military agencies and has applied, or is applying, for non-dilutive funding opportunities, and describes seclidemstat, an investigational LSD1 inhibitor from its legacy oncology portfolio, as available for license or sale. Cash was $8.1 million at September 30, 2026, including about $2.5 million of restricted Gates Foundation grant funding, and 2,385,282 shares of common stock were outstanding. The release does not include financial statements or a conference call. Primary source. Applying for funding is not an award, and preclinical dosing potential is not human evidence.
September 29, 2026 update. The September 29 question is whether prolonged tissue exposure can translate into a safe and protective human regimen. Drug retention is one component of that chain. It does not show prevention of infection, reduction in hospitalization or benefit in an immunocompromised patient. These outcomes require appropriately designed human studies. Company source
Preclinical exposure is not human antiviral efficacy. DCOY-CoV has no reported human efficacy result. Restricted grant cash cannot fund every corporate purpose, and continuing operations require financing; warrant and resale capacity are not cash received.
The constructive case
Preclinical tissue exposure for up to seven days supports studying a once-weekly intranasal DCOY-CoV regimen. If reproducible and tolerable in humans, that profile could support a practical development program. The company’s most recent guidance (November 3) is a CTA or IND filing in the second half of 2027 ahead of a Phase 1 trial. September 29 source
The cautious case
Tissue retention is not proven antiviral protection in people. Clinical translation, safety, manufacturing and financing remain unresolved. The September 23 warrant closing raised about $3.85 million gross but also introduced new warrants; it is not funding for the entire clinical program. September 29 source
Latest Decoy Therapeutics news
Nov 3, 2026
Decoy Therapeutics provides third quarter 2026 business update
Decoy Therapeutics expects to file a CTA or IND application in 2H 2027 to begin a Phase 1 trial of its pan-coronavirus candidate. In preclinical studies, the optimized lead candidate showed potential for once-weekly dosing, compared to daily dosing for earlier candidates. Cash on balance sheet was $8.1 million at September 30, 2026, including approximately $2.5 million in restricted Gates Foundation grant funding.
Oct 16, 2026
Resale registration for the 2,368,868 new-warrant shares declared effective
Decoy filed a Form S-1 (File No. 333-299353) on October 7, 2026 to register the resale of up to 2,368,868 common shares issuable on exercise of the new warrants issued in the September 23 inducement placement. The SEC declared it effective on October 16, 2026, and the final prospectus was filed the same day. The new warrants carry a $3.25 exercise price, are immediately exercisable and expire five years after issuance; the company receives proceeds only from cash exercises. The prospectus reports 2,385,282 shares outstanding on October 6, 2026 and cash, cash equivalents and restricted cash of approximately $8.0 million at September 30, 2026, of which $2.5 million is restricted under the Gates Foundation grant. Prospectus Notice of effectiveness Form S-1 .
Oct 7, 2026
Resale registration statement filed
The S-1 registered possible resale of 2,368,868 new-warrant shares. Its later October 16 effectiveness is described separately; registration does not mean exercise, issued shares or proceeds from resale received by Decoy.
Oct 1, 2026
CEO presentation at The Small Cap Showcase
The September 30 announcement scheduled a corporate overview by Rick Pierce at 11:30 a.m. ET on October 1 in New York, with one-on-one investor meetings, at a single-day conference of about ten small-cap companies. It adds no new data or financing; the lead program is described as advancing toward the clinic.
Sep 29, 2026
DCOY-CoV: up to seven days of tissue exposure in preclinical PK
In preclinical studies a single intranasal dose kept drug levels above designed antiviral concentrations for up to seven days in nasal mucosal and lung tissue. Chief technology officer Michael Lipp presented the data at the Boulder Peptide Symposium’s Peptide Showcase. Clinical entry is guided to 2027.
Sep 22, 2026
Series B warrants exercised at $3.25; new warrants issued
The holder exercised all 1,184,434 Series B warrants at a strike cut from $5.91 to $3.25, for about $3.85 million gross, and received immediately exercisable new warrants on 2,368,868 shares at $3.25. A corrective release clarified that no shareholder approval is needed.
DCOY stock catalysts: development and reporting dates
- November 3, 2026 — Third-quarter 2026 business update: cash $8.1 million and 2,385,282 shares at September 30. Completed
- Second half of 2027 — CTA or IND filing for the Phase 1 trial of the pan-coronavirus candidate; Phase 2a human challenge trial at hVivo afterwards. Company expectation, no exact day
November 3 business update · October resale prospectus · Primary IR index
Decoy antiviral platform and preclinical limits
Many enveloped viruses enter cells through a fusion process. Decoy designs peptide conjugates intended to interfere with elements of that machinery. Its proposition is that shared structural features may permit activity across more than one virus, while a common design-and-testing process supports subsequent candidates. The company’s September 29 description lists programmes in coronaviruses (COVID-19, MERS), paramyxoviruses (RSV, hPIV, Nipah, measles) and filoviruses (Ebola, Marburg); only the coronavirus and filovirus work has reported data in 2026. IMP³ACT combines computational design, laboratory synthesis and experimental feedback. AI can help select molecules worth testing; it cannot replace the tests. A candidate still needs a useful concentration at the relevant tissue, sufficient stability, acceptable safety and a reproducible manufacturing process.
DCOY cash restrictions and warrant exposure
At June 30, total cash, cash equivalents and restricted cash were $8,289,108. Approximately $2.7 million was restricted under the Gates Foundation grant. The cash figure therefore cannot all be treated as freely deployable capital for a new filovirus programme. First-half operating cash use was $5,541,348. Stockholders’ equity was $4,320,906 and total liabilities were $4,680,254. The filing said existing resources were expected to support restructured operations into late 2026 and disclosed substantial doubt about continuing as a going concern. These June figures are the company’s statements at filing. On November 3 the company reported cash of $8.1 million at September 30, 2026, including about $2.5 million of restricted Gates Foundation grant funding. The release gives no runway estimate and no statement of operating cash use. The same filing lists, among its risks, the ability to keep complying with the Nasdaq minimum stockholders’ equity requirement of $2.5 million: against equity of $4,320,906 on June 30 and a first-half net loss of $4,598,428, that margin is what any further cash consumption erodes, and the company writes that non-compliance would affect the liquidity and trading of its shares.
Merlintrader Health Score · $DCOY
1.65out of 5
Assessed October 2, 2026, before the November 3 business update; the scores and the text of each pillar are those of that assessment. Weighted calculation: 1.5×30% + 2.0×30% + 1.0×20% + 1.5×10% + 2.5×10% = 1.65. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- DCOY-CoV has no reported human efficacy result. Restricted grant cash cannot fund every corporate purpose, and continuing operations require financing; warrant and resale capacity are not cash received.
- Tissue retention is not proven antiviral protection in people. Clinical translation, safety, manufacturing and financing remain unresolved. The September 23 warrant closing raised about $3.85 million gross but also introduced new warrants; it is not funding for the entire clinical program. September 29 source
DCOY Stock FAQ: Decoy Therapeutics Questions Answered
When does Decoy expect to start clinical trials?
Decoy’s most recent guidance, in its November 3, 2026 business update, is to file a CTA or IND application in the second half of 2027 to start a Phase 1 trial of its pan-coronavirus candidate, followed by a Phase 2a human challenge trial at hVivo. The September 29 update, which concerned DCOY-CoV, had pointed to clinical entry in 2027. Both are company targets with no exact day, and financing, preclinical work and trial preparation remain relevant to execution. November 3 business update. DCOY-CoV development timeline.
Does Decoy have FDA approval for its antiviral drugs?
Decoy’s September 2026 announcements describe investigational programs rather than FDA-approved antiviral drugs. The company is exploring an Animal Rule pathway for its pan-filovirus program and, on November 3, said it expects to file a CTA or IND application for its pan-coronavirus candidate in the second half of 2027. Exploring a regulatory route and seeking non-dilutive funding do not establish an accepted application or an approval decision. Proposed filovirus regulatory strategy. DCOY-CoV preclinical status.
How much cash does DCOY have and is funding a concern?
Decoy’s November 3, 2026 business update reported cash of $8.1 million at September 30, 2026, including about $2.5 million of restricted Gates Foundation grant funding; the October 16, 2026 prospectus had shown approximately $8 million on a preliminary basis. At June 30, the total was $8,289,108, including approximately $2.7 million restricted. The June-quarter filing disclosed substantial doubt about continuing as a going concern and $5,541,348 first-half operating cash use. That filing projected funding into late 2026, before the September warrant financing. September 30 cash and restricted funds (company release). September liquidity and restrictions. June cash, six-month cash flows and going-concern disclosure.
How many new warrants did Decoy issue and could they dilute DCOY?
Decoy issued warrants for up to 2,368,868 shares on September 23, 2026, exercisable immediately at $3.25 for five years. Series A and C milestone warrants were also repriced from $5.91 to $3.25. The October prospectus reported 2,385,282 common shares outstanding on October 6, and the November 3 business update reported the same number at September 30. Resales generate no company proceeds; future cash warrant exercises are a separate possible funding source. New warrant and repricing terms. October share count and resale proceeds.
When will Decoy Therapeutics report its next earnings?
On November 3, 2026 Decoy published a third-quarter business update with cash of $8.1 million and 2,385,282 shares outstanding at September 30; it includes no financial statements and no conference call, and it does not give a date for the next quarterly report. Third-quarter 2026 business update. Decoy company announcements. Decoy investor events.
What does Decoy Therapeutics do?
Decoy Therapeutics develops experimental peptide-based antivirals designed to target viral-entry mechanisms shared across virus families, according to its September 29, 2026 announcement. Its IMP³ACT platform combines computational design with peptide-conjugate chemistry. The pipeline includes coronavirus, paramyxovirus and filovirus programs; lead DCOY-CoV is being developed as an intranasal candidate and remains preclinical. Decoy platform and pipeline description.
What did Decoy’s once-weekly DCOY-CoV results actually show?
Decoy reported preclinical pharmacokinetic findings on September 29, 2026: after one intranasal dose, drug levels remained above company-designed antiviral concentrations for up to seven days in nasal mucosal and lung tissue. These exposure findings support studying weekly dosing. They are not human evidence of preventing infection, reducing hospitalization or protecting immunocompromised patients. Preclinical tissue-exposure findings.
How much money did Decoy raise in September 2026?
Decoy raised approximately $3.85 million gross, before fees and expenses, in the warrant transaction that closed September 23, 2026. The holder exercised 1,184,434 Series B warrants at the reduced $3.25 exercise price. The company intended to use the net proceeds for working capital and other general corporate purposes. September warrant exercise and closing proceeds.
Primary sources
- November 3, 2026 · Third quarter 2026 business update
- October 16, 2026 · Resale registration for the 2,368,868 new-warrant shares declared effective
- October 1, 2026 · CEO presentation at The Small Cap Showcase
- September 29, 2026 · DCOY-CoV: up to seven days of tissue exposure in preclinical PK
- September 22, 2026 · Series B warrants exercised at $3.25; new warrants issued
- September 22, 2026 · Pan-filovirus program and a possible Animal Rule route
- Primary IR index
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent educational research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $DCOY or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
